Literature DB >> 10620653

Decreased color discrimination and contrast sensitivity in Parkinson's disease.

V Pieri1, N J Diederich, R Raman, C G Goetz.   

Abstract

Patients with Parkinson's disease (PD) often complain of blurred vision or even of distinctive visual disturbances like hallucinations and illusions. Recent studies have emphasized the potential influence of primary visual deficits of color and contrast discrimination. To study primary visual function, we studied color discrimination (CD) and contrast sensitivity (CS) during 'on' medication in PD patients and compared them to non-PD subjects. Twenty one PD patients were compared to 30 age-matched controls using CD tested by the D-15 Lanthony test (D15) and the Farnsworth-Munsell 100 Hue test (FM) and CS tested by the Pelli-Robson (PL) and the Vis-Tech tables (VT). We excluded subjects with a visual acuity </=0.6 Snellen fraction or known ophthalmological diseases. PD patients showed greater impairment on all visual tests than controls. This difference was significant for the FM test (P<0.001), the spatial frequencies 12 and 18 cpd (cycles per degree) of the VT test (P<0.05) and both the monocular and binocular PR tests (P<0.05). Most tests for CS and CD showed statistical independency. CS deficits, but not CD deficits, correlated with age in both patients and controls. This study documents major and independent impairment of both color and contrast discrimination in PD patients. Further studies should elucidate possible clinical implications and correlations, such as the frequency of falls or visual hallucinations.

Entities:  

Mesh:

Year:  2000        PMID: 10620653     DOI: 10.1016/s0022-510x(99)00204-x

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  42 in total

1.  The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease.

Authors:  James M Shine; Glenda M Halliday; Moran Gilat; Elie Matar; Samuel J Bolitho; Maria Carlos; Sharon L Naismith; Simon J G Lewis
Journal:  Hum Brain Mapp       Date:  2013-06-13       Impact factor: 5.038

2.  Relation of Parkinson's disease subtypes to visual activities of daily living.

Authors:  Daniel R Seichepine; Sandy Neargarder; Ivy N Miller; Tatiana M Riedel; Grover C Gilmore; Alice Cronin-Golomb
Journal:  J Int Neuropsychol Soc       Date:  2011-08-04       Impact factor: 2.892

3.  Novel n-back spatial working memory task using eye movement response.

Authors:  Cameron B Jeter; Saumil S Patel; Anne B Sereno
Journal:  Behav Res Methods       Date:  2011-09

4.  Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson disease.

Authors:  A Ridder; M L T M Müller; V Kotagal; K A Frey; R L Albin; N I Bohnen
Journal:  Parkinsonism Relat Disord       Date:  2016-10-07       Impact factor: 4.891

5.  Contrast sensitivity visual acuity in REM sleep behavior disorder: a comparison with and without Parkinson disease.

Authors:  Whitney H Whitfield; Garrett Q Barr; Matthew J Khayata; Peggy H Vogt; Eric M Keasler; Jacqueline M Sanchez; Ziyan Song; Marvin Dieujuste; Brandon Cardon; Ryan Riggs; Karina N Pique; Elliot Merin; David Y Huang; Charles G Maitland
Journal:  J Clin Sleep Med       Date:  2020-01-14       Impact factor: 4.062

6.  Contrast sensitivity and visual hallucinations in patients referred to a low vision rehabilitation clinic.

Authors:  M L Jackson; K Bassett; P V Nirmalan; E C Sayre
Journal:  Br J Ophthalmol       Date:  2006-10-11       Impact factor: 4.638

7.  Color vision: a study of essential tremor cases versus normal controls.

Authors:  E D Louis; M Gerbin; A S Viner
Journal:  Eur J Neurol       Date:  2012-03-15       Impact factor: 6.089

8.  Normal discrimination of spatial frequency and contrast across visual hemifields in left-onset Parkinson's disease: evidence against perceptual hemifield biases.

Authors:  Daniel J Norton; Abhishek Jaywant; Xavier Gallart-Palau; Alice Cronin-Golomb
Journal:  Vision Res       Date:  2014-12-11       Impact factor: 1.886

9.  Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans.

Authors:  Matthew J Baggott; Jennifer D Siegrist; Gantt P Galloway; Lynn C Robertson; Jeremy R Coyle; John E Mendelson
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

10.  Visual dysfunction in patients with Parkinson's disease and essential tremor.

Authors:  Ivanka Štenc Bradvica; Mario Bradvica; Suzana Matić; Patricia Reisz-Majić
Journal:  Neurol Sci       Date:  2014-08-28       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.